Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAFA antisense RNA 1 (MAFA-AS1) is a long non-coding RNA (lncRNA) that is transcribed in the antisense orientation relative to the MAFA gene[2][3]. It does not encode a protein. Studies indicate MAFA-AS1 can regulate gene expression epigenetically, potentially repressing or activating the expression of the MAFA gene, which may influence cellular differentiation programs[2]. In cancer biology, particularly hepatocellular carcinoma (HCC), MAFA-AS1 has been identified as a prognostic marker associated with poor overall and disease-free survival[1]. Analyses suggest its involvement in tumorigenic progression, possibly through interactions with splicing regulators (such as SRSF1/SRSF9) and microRNAs (for example, miR210)[1]. As a lncRNA, MAFA-AS1 is not a traditional therapeutic target like a receptor or enzyme, but it may serve as a molecular biomarker or a potential future target for RNA-based intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MAFA antisense RNA 1 (MAFA-AS1).